Clinical Trials
19 trialsNCT06813118 2026-05-07
Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case
HITEC-Institute of Medical Sciences
Phase 1 Completed
NCT04895761 2026-04-13
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Providence Health & Services
Phase 1 Active not recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT06139107 2025-11-14
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
Phase 1 Recruiting
NCT03959891 2025-09-29
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03900884 2024-11-07
PALVEN
Peter MacCallum Cancer Centre, Australia
Phase 1 Active not recruiting
NCT01791478 2024-07-23
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Active not recruiting
NCT04177693 2023-06-05
Pharmacokinetics and Hepatic Safety of EGCG
Yale University
Phase 1 Completed
NCT04872608 2023-04-28
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT03128619 2022-09-26
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT02152943 2020-12-19
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02619669 2020-03-12
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn
NCT02619162 2019-07-23
Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 1 Completed
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT00516542 2012-07-24
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00945360 2012-07-13
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
American University of Beirut Medical Center
Phase 1 Withdrawn